Irina N Krasnova1, Zuzana Justinova2, Jean Lud Cadet3. 1. Molecular Neuropsychiatry Research Branch, Intramural Research Program, NIDA, NIH, DHHS, 251 Bayview Blvd, Baltimore, MD, 21224, USA. ikrasnov@intra.nida.nih.gov. 2. Behavioral Neuroscience Research Branch, Intramural Research Program, NIDA, NIH, DHHS, Baltimore, MD, 21224, USA. 3. Molecular Neuropsychiatry Research Branch, Intramural Research Program, NIDA, NIH, DHHS, 251 Bayview Blvd, Baltimore, MD, 21224, USA. JCADET@intra.nida.nih.gov.
Abstract
RATIONALE AND OBJECTIVES: Addiction to psychostimulant methamphetamine (METH) remains a major public health problem in the world. Animal models that use METH self-administration incorporate many features of human drug-taking behavior and are very helpful in elucidating mechanisms underlying METH addiction. These models are also helping to decipher the neurobiological substrates of associated neuropsychiatric complications. This review summarizes our work on the influence of METH self-administration on dopamine systems, transcription and immune responses in the brain. METHODS: We used the rat model of METH self-administration with extended access (15 h/day for eight consecutive days) to investigate the effects of voluntary METH intake on the markers of dopamine system integrity and changes in gene expression observed in the brain at 2 h-1 month after cessation of drug exposure. RESULTS: Extended access to METH self-administration caused changes in the rat brain that are consistent with clinical findings reported in neuroimaging and postmortem studies of human METH addicts. In addition, gene expression studies using striatal tissues from METH self-administering rats revealed increased expression of genes involved in cAMP response element binding protein (CREB) signaling pathway and in the activation of neuroinflammatory response in the brain. CONCLUSION: These data show an association of METH exposure with activation of neuroplastic and neuroinflammatory cascades in the brain. The neuroplastic changes may be involved in promoting METH addiction. Neuroinflammatory processes in the striatum may underlie cognitive deficits, depression, and parkinsonism reported in METH addicts. Therapeutic approaches that include suppression of neuroinflammation may be beneficial to addicted patients.
RATIONALE AND OBJECTIVES: Addiction to psychostimulant methamphetamine (METH) remains a major public health problem in the world. Animal models that use METH self-administration incorporate many features of human drug-taking behavior and are very helpful in elucidating mechanisms underlying METH addiction. These models are also helping to decipher the neurobiological substrates of associated neuropsychiatric complications. This review summarizes our work on the influence of METH self-administration on dopamine systems, transcription and immune responses in the brain. METHODS: We used the rat model of METH self-administration with extended access (15 h/day for eight consecutive days) to investigate the effects of voluntary METH intake on the markers of dopamine system integrity and changes in gene expression observed in the brain at 2 h-1 month after cessation of drug exposure. RESULTS: Extended access to METH self-administration caused changes in the rat brain that are consistent with clinical findings reported in neuroimaging and postmortem studies of humanMETH addicts. In addition, gene expression studies using striatal tissues from METH self-administering rats revealed increased expression of genes involved in cAMP response element binding protein (CREB) signaling pathway and in the activation of neuroinflammatory response in the brain. CONCLUSION: These data show an association of METH exposure with activation of neuroplastic and neuroinflammatory cascades in the brain. The neuroplastic changes may be involved in promoting METH addiction. Neuroinflammatory processes in the striatum may underlie cognitive deficits, depression, and parkinsonism reported in METH addicts. Therapeutic approaches that include suppression of neuroinflammation may be beneficial to addictedpatients.
Authors: B Ladenheim; I N Krasnova; X Deng; J M Oyler; A Polettini; T H Moran; M A Huestis; J L Cadet Journal: Mol Pharmacol Date: 2000-12 Impact factor: 4.436
Authors: Annette E Fleckenstein; Trent J Volz; Evan L Riddle; James W Gibb; Glen R Hanson Journal: Annu Rev Pharmacol Toxicol Date: 2007 Impact factor: 13.820
Authors: Matthew J Robson; Ryan C Turner; Zachary J Naser; Christopher R McCurdy; James P O'Callaghan; Jason D Huber; Rae R Matsumoto Journal: Exp Neurol Date: 2014-02-06 Impact factor: 5.330
Authors: Irina N Krasnova; Amber B Hodges; Bruce Ladenheim; Raina Rhoades; Crystal G Phillip; Angela Cesena; Ekaterina Ivanova; Christine F Hohmann; Jean Lud Cadet Journal: Neurosci Res Date: 2009-06-24 Impact factor: 3.304
Authors: Christopher S Walker; Ann C Raddant; Michael J Woolley; Andrew F Russo; Debbie L Hay Journal: Cephalalgia Date: 2017-02-06 Impact factor: 6.292
Authors: Subhash Chand; Austin Gowen; Mason Savine; Dalia Moore; Alexander Clark; Wendy Huynh; Niming Wu; Katherine Odegaard; Lucas Weyrich; Rick A Bevins; Howard S Fox; Gurudutt Pendyala; Sowmya V Yelamanchili Journal: J Extracell Vesicles Date: 2021-12
Authors: Arvie Abiero; Chrislean Jun Botanas; Raly James Custodio; Leandro Val Sayson; Mikyung Kim; Hyun Jun Lee; Hee Jin Kim; Kun Won Lee; Youngdo Jeong; Joung-Wook Seo; In Soo Ryu; Yong Sup Lee; Jae Hoon Cheong Journal: Psychopharmacology (Berl) Date: 2019-12-11 Impact factor: 4.530